Compare AU
Compare CURE vs. RCAP
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the Resolution Cap Global Prop Sec (Managed Fund) (RCAP). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | RCAP | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 82 | 3 |
Median incremental investment | $619.50 | $6,993.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,323.41 | $9,879.43 |
Average age group | > 35 | > 35 |
Key Summary
CURE | RCAP | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | RCAP.AX was created on 2022-02-22 by Resolution Capital. The fund's investment portfolio concentrates primarily on real estate equity. The Fund aims to achieve an annual total return that exceeds the total return of the Benchmark after fees on a rolling 3 year basis |
Top 3 holdings | Natera Inc (3.41 %) Incyte Corp (2.94 %) Gilead Sciences Inc (2.88 %) | Welltower Inc (8.78 %) Digital Realty Trust Inc (7.11 %) Equinix Inc (6.88 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Real Estate (100.00 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | United States (60.84 %) United Kingdom of Great Britain and Northern Ireland (11.25 %) France (6.53 %) |
Management fee | 0.45 % | 0.8 % |
Key Summary
CURE | RCAP | |
|---|---|---|
Issuer | Global X | Resolution Capital |
Tracking index | S&P Biotechnology Select Industry | |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.8 % |
Price | $49.94 | $1.63 |
Size | $38.065 million | N/A |
10Y return | N/A | 8.87 % |
Annual distribution yield (5Y) | 4.24 % | 1.59 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 21/02/2022 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | RCAP | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 82 | 3 |
Median incremental investment | $619.50 | $6,993.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,323.41 | $9,879.43 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | RCAP | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | RCAP |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |